Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

The drug combination was safe and showed promise in treating advanced tumors.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Recognizing and treating related skin conditions can improve atopic dermatitis management.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Abatacept may help some people with alopecia areata regrow hair.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.

Enhancing Tregs can protect against alopecia areata.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Upadacitinib may effectively treat alopecia areata without side effects.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Mesenchymal stem cells may effectively treat and prevent allergic skin conditions.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.